A randomized US trial evaluated whether a shortened course of romosozumab followed by denosumab could achieve bone mineral density improvements comparable to the standard 12-month romosozumab regimen in...
A retrospective cohort study examined whether concurrent menopause hormone therapy modifies weight loss and cardiometabolic outcomes among postmenopausal women with overweight or obesity treated with...
On November 10, the U.S. Department of Health and Human Services announced that the FDA is initiating the removal of certain black box warnings from hormone replacement therapy products for menopause,...
A large cohort study of nearly 1000 women with multiple sclerosis (MS) found that menopause does not accelerate disability progression or increase the risk of transitioning to secondary progressive MS.
...
A new analysis of the Women’s Health Initiative trials found that menopausal hormone therapy effectively reduces vasomotor symptoms without increasing cardiovascular risk in women aged 50 to 59 years....
Anuradha Krishnan, BA, research analyst at dQ&A, previews her presentation at the 2025 American Diabetes Association Scientific Sessions, sharing findings from a multi-country survey examining how...
A new analysis of more than 42,000 cases reveals that uterine serous carcinoma is almost exclusively a postmenopausal disease, with less than 2% of cases diagnosed before age 52 — highlighting menopause,...
In this interview, Jeffrey Levine, MD, MPH, previews his Practical Updates in Primary Care 2025 presentation on managing menopause across life stages. He discusses the impact of hormonal changes on mental...
An ultra-low-dose 0.005% estriol vaginal gel reduced recurrent urinary tract infections in postmenopausal women with genitourinary syndrome of menopause, offering a safe and effective alternative to...
